BEAM Beam Therapeutics Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
02:12
Sep 10
Sep 10
Bought BEAM at 25 as good entry
The author bought BEAM because 25 is described as a usually good entry level for the stock. The rationale is purely a price-level/entry heuristic rather than a fundamental catalyst, and no explicit risk or time horizon is given.
MED
16:44
Aug 11
Aug 11
Author defends holding BEAM tokens and buying out team members.
Author defends holding BEAM tokens and buying out team members, rebutting a dump accusation without stating a current position or forward view.
15:47
Jul 01
Jul 01
Author clarifies personal history with Sophon and Beam, defends Beam's treasury and token burns.
Author clarifies personal history with Sophon and Beam, defends Beam's treasury and token burns, but does not express a forward-looking trade view.
LOW
10:18
Jun 25
Jun 25
Buy BEAM as a beneficiary of quantum computing and AI-driven biotech breakthroughs.
Buy BEAM as a beneficiary of quantum computing and AI-driven biotech breakthroughs; author sees these technologies as catalysts for transformative drug discovery including cancer cures and regenerative medicine.
MED
12:03
Jun 24
Jun 24
Author flags BEAM as facing difficulty in an IP theft dispute with BOLD.
Author flags BEAM as facing difficulty in an IP theft dispute with BOLD, describing the situation as egregious; no explicit directional position stated.
MED
23:56
Apr 28
Apr 28
Beam is too speculative, avoid.
Beam Therapeutics is a speculative, heavily shorted biotech with no earnings. Unless they have something that saves lives, move on.
MED
21:52
Mar 02
Mar 02
In the outro, Becky Quick teases the next episode featuring a child who received a "personalized CRISPR-based gene editing therapy" that likely saved his life. While a teaser, this highlights the shift of CRISPR technology from theoretical research to applied clinical success ("miracles"). Positive real-world outcomes in rare diseases validate the platforms of major gene-editing companies, justifying premium valuations for their pipelines. Long the CRISPR innovators as clinical validation accelerates. Regulatory hurdles; high cost of personalized therapies limiting total addressable market (TAM).
About BEAM Analyst Coverage
Buzzberg tracks BEAM (Beam Therapeutics Inc. Common Stock) across 5 sources. 1 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (14%). 7 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: u/Valkyrie_Skuld, Pentosh1, asklivermore.